Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Not yet recruiting 30 enrolled Xiuchao Wang

NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy and safety of Rimegepant combined with AG chemotherapy as first-line treatment for metastatic pancreatic cancer.

Timeline

Start: 2026-03
Primary completion: 2028-12
Completion: 2028-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	125 mg/m2	Intravenous
Subject	Rimegepant	Small molecule	75 mg	—

Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma

Summary

Timeline

Drugs

Indications